Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mu, kappa, and delta opioid receptors are class A G protein-coupled receptors primarily expressed in the central and peripheral nervous system, as well as other tissues. They bind endogenous opioid peptides (endorphins, enkephalins, dynorphins) and exogenous opioids (morphine, fentanyl, etc.), mediating analgesic effects as well as side effects such as euphoria, addiction, and respiratory depression. Each receptor subtype has distinct tissue distribution, endogenous ligand preference, and physiological roles: - Mu opioid receptor (MOR): Most widely expressed, vital for analgesia, respiratory depression, euphoria, dependence, and gastrointestinal effects. - Kappa opioid receptor (KOR): Mediates analgesia, diuresis, and dysphoria, and may have lower abuse potential for agonists. - Delta opioid receptor (DOR): Contributes to analgesia and mood regulation, with potential roles in inflammatory pain and psychiatric disorders. Opioid receptors remain critical therapeutic targets for pain and addiction, but clinical use is complicated by serious adverse effects and misuse potential. Recent research seeks biased ligands to enhance therapeutic benefit while minimizing harm
Agonists: Bind and activate the receptor, leading to Gi/o protein signaling, inhibition of adenylyl cyclase, decreased cAMP, opening of potassium channels, closing of calcium channels, inhibition of neurotransmitter release (presynaptic), reduced neuronal excitability, and promotion of analgesia and other opioid effects Antagonists: Block receptor activation, preventing endogenous or exogenous ligand effects Biased agonists: Preferentially activate G protein- or β-arrestin–mediated pathways, potentially reducing side effects such as respiratory depression or dependence
16 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mu, kappa, and delta opioid receptor (MOR, KOR, DOR).